XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Full Enrollment of Phase 3 4WARD Trial Expected in 2H25 X4 ...

In the assessment of 12-month price targets, analysts unveil insights for X4 Pharmaceuticals, presenting an average target of ...

Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line ...

Q4 2024 Management View CEO Paula Ragan highlighted 2024 as a transformative year for X4 Pharmaceuticals, with the U.S. approval and launch of XOLREMDI (mavorixafor) for WHIM syndrome, a rare ...

X4 Pharmaceuticals Inc (XFOR) navigates a challenging landscape with strategic cost reductions and promising product ...

Reports Q4 revenue $1.4M vs. $0 last year. “As expected, 2024 was a transformative year for the company and our momentum has continued into ...

Before thousands of people flock to downtown Salt Lake City to attend the Qualtrics X4 summit, the Provo-born company on ...

BOSTON (AP) — BOSTON (AP) — X4 Pharmaceuticals, Inc. (XFOR) on Tuesday reported a loss of $39.8 million in its fourth quarter. On a per-share basis, the Boston-based company said it had a loss of 20 ...

If you buy something via one of our links, we may earn a commission. As a massive fan of the Insta360 X3, I was thrilled when a brand-new X4 arrived at my doorstep for testing earlier this season. The ...

M.2 2230 PCIe Gen 4 x4 SSD reaching 7,300MB/sPNY has unveiled its new CS2342 M.2 2230 NVMe PCIe Gen 4 x4 SSD, which promises ...